Sofosbuvir Use in the Setting of End-stage Renal Disease:A Single Center Experience

作     者：Avin Aggarwal Eric R.Yoo Ryan B.Perumpail George Cholankeril Radhika Kumari Tami J.Daugherty Alex S.Lapasaran Aijaz Ahmed 

作者机构：Division of Gastroenterology and HepatologyStanford University School of MedicineStanfordCAUSA Department of MedicineUniversity of Illinois College of MedicineChicagoILUSA Division of Gastroenterology and HepatologyUniversity of Tennessee Health Sciences CenterMemphisTNUSA Digestive Health AssociatesRenoNVUSA 

出 版 物：《Journal of Clinical and Translational Hepatology》 (临床与转化肝病杂志（英文版）)

年 卷 期：2017年第5卷第1期

页      面：23-26页

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Gilead SciencesGilead Sciences 

主　　题：Hepatitis C End-stage renal disease Sofosbuvir Direct-acting antivirals 

摘      要：Background and Aims:Patients with chronic hepatitis C (CHC) and end-stage renal disease (ESRD) who are dialysisdependent form a unique group,in which safety,tolerability and efficacy of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) need further ***:We performed a retrospective analysis of 14 patients with CHC and ESRD on dialysis who received 15 courses of SOF-based *** evaluated dose escalation to standard-dose SOF in this proof-of-principle ***:Sustained virological response (defined as undetectable viral load at 12 weeks,SVR-12) was achieved in 13 out of the 15 (86.7%) treatment *** (46.6%) patients received reduced half dose as conservative proof-of-principal to mitigate potential *** 13 out of 15 treatment courses,patients completed the designated treatment *** patient was treated twice and developed SVR-12 with the *** patient was lost to follow-up and counted as a *** discontinuations were not due to DAA-related adverse *** were no reports of severe adverse effects or drug ***:We treated CHC patients with ESRD using dose escalation to standard-dose SOF in this proof-of-principle experience and achieved SVR rates comparable to general population.